Research programme: oncology therapeutics - AI Proteins
Latest Information Update: 10 May 2024
At a glance
- Originator AI Proteins
- Class Antineoplastics; Immunotherapies; Proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 03 Apr 2024 Preclinical trials in Cancer in USA (Unspecified) (AI proteins pipeline, April 2024)